Replacement Parts After Repair: Compatibility Evidence and Remanufacturing Risk
How clinical engineering teams evaluate replacement parts under FDA's May 2024 remanufacturing guidance, QMSR 21 CFR 820, Figure 1, and CMS return-to-service rules.
By
Category
Replacement parts, supplier qualification, traceability, and compatibility evidence.
How clinical engineering teams evaluate replacement parts under FDA's May 2024 remanufacturing guidance, QMSR 21 CFR 820, Figure 1, and CMS return-to-service rules.
By